Cargando…

Inflammatory bowel disease induced by bimekizumab

Detalles Bibliográficos
Autores principales:	Wietrzykowska-Grishanovich, Dominika, Pleskacz, Maciej, Kempiński, Radosław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165330/ https://www.ncbi.nlm.nih.gov/pubmed/35664026 http://dx.doi.org/10.5114/pg.2022.116374

Ejemplares similares

Biochemical Intracystic Biomarkers in the Differential Diagnosis of Pancreatic Cystic Lesions
por: Wietrzykowska-Grishanovich, Dominika, et al.
Publicado: (2022)

Ultrasound Elastography in the Assessment of the Intestinal Changes in Inflammatory Bowel Disease—Systematic Review
por: Ślósarz, Dominika, et al.
Publicado: (2021)

Cumulative Effective Dose from Medical Imaging in Inflammatory Bowel Disease
por: Łukawska, Agata, et al.
Publicado: (2021)

Bimekizumab for plaque psoriasis
Publicado: (2022)

Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults
por: Krzystek-Korpacka, Małgorzata, et al.
Publicado: (2020)

Sub‐erythrodermic psoriasis successfully treated with bimekizumab: A case report
por: Valenti, Mario, et al.
Publicado: (2022)

Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review
por: Krzystek-Korpacka, Małgorzata, et al.
Publicado: (2020)

Review of bimekizumab in the treatment of psoriasis
por: Koppu, Sindhuja, et al.
Publicado: (2022)

Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis
por: Bromke, Mariusz A., et al.
Publicado: (2021)

Tremor in Patients with Inflammatory Bowel Disease
por: De Oliveira, Gisele R., et al.
Publicado: (2013)

Bimekizumab: the new drug in the biologics armamentarium for psoriasis
por: Freitas, Egídio, et al.
Publicado: (2021)

Familial inflammatory bowel diseases in Northwest Greece
por: Katsanos, Konstantinos H., et al.
Publicado: (2015)

Inflammatory Bowel Disease and the Risk of Herpes Zoster
por: Lai, Shih-Wei
Publicado: (2019)

Therapeutic drug monitoring in inflammatory bowel disease treatments
por: Wang, Meng-Yao, et al.
Publicado: (2022)

Alterations of pulmonary function in patients with inflammatory bowel diseases
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2017)

Plant-Based Diet Recommended for Inflammatory Bowel Disease
por: Chiba, Mitsuro, et al.
Publicado: (2023)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Inflammatory bowel disease and diabetes: Is there a link between them?
por: Sang, Miao-Miao, et al.
Publicado: (2022)

Urotensin II level is elevated in inflammatory bowel disease patients
por: Zhang, Yan, et al.
Publicado: (2022)

MDR1C3435T Polymorphism and Inflammatory Bowel Disease
por: Malik, Manzoor A.
Publicado: (2015)

Comment on “Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease”
por: Lai, Wenwen, et al.
Publicado: (2018)

Extraintestinal manifestations of pediatric inflammatory bowel disease in Saudi Arabia
por: Al-Mendalawi, Mahmood D.
Publicado: (2018)

Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases
por: Brenner, Erica J., et al.
Publicado: (2021)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Transcriptional and Metabolomic Analysis of L-Arginine/Nitric Oxide Pathway in Inflammatory Bowel Disease and Its Association with Local Inflammatory and Angiogenic Response: Preliminary Findings
por: Krzystek-Korpacka, Małgorzata, et al.
Publicado: (2020)

Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape
por: Papa, Alfredo, et al.
Publicado: (2021)

Diet and nutrition against inflammatory bowel disease: Trick or treat(ment)?
por: Greco, Salvatore, et al.
Publicado: (2022)

What Might be the Cause for the Emerging Inflammatory Bowel Disease in Saudi Outpatients?
por: Qin, Xiaofa
Publicado: (2014)

Adsorptive Leukocytapheresis in Inflammatory Bowel Diseases: Our Preliminary Results are Encouraging
por: Törüner, Murat, et al.
Publicado: (2013)

The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease
por: Biancardi, Ana Luiza, et al.
Publicado: (2019)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
por: Oliveira, Daniel G, et al.
Publicado: (2021)

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives
por: Camiña-Conforto, Gemma, et al.
Publicado: (2023)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

Immunosuppressive regimens and outcomes of inflammatory bowel disease patients requiring kidney transplantation
por: Singh, Urvashi, et al.
Publicado: (2022)

Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place
por: Truta, Brindusa
Publicado: (2022)

Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol–thiopurine cotherapy
por: Simsek, Melek, et al.
Publicado: (2018)

Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020)

COVID-19 and Inflammatory Bowel Disease: Questions on Incidence, Severity, and Impact of Treatment?
por: Caron, Benedicte, et al.
Publicado: (2020)

Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients
por: Fortes, Flora Maria Lorenzo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_buj9lja5ap6chgadrc6nqpab3m